"Liver Cirrhosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Descriptor ID |
D008103
|
MeSH Number(s) |
C06.552.630
|
Concept/Terms |
Liver Cirrhosis- Liver Cirrhosis
- Cirrhosis, Liver
- Cirrhoses, Liver
- Liver Cirrhoses
- Hepatic Cirrhosis
- Cirrhoses, Hepatic
- Cirrhosis, Hepatic
- Hepatic Cirrhoses
|
Below are MeSH descriptors whose meaning is more general than "Liver Cirrhosis".
Below are MeSH descriptors whose meaning is more specific than "Liver Cirrhosis".
This graph shows the total number of publications written about "Liver Cirrhosis" by people in this website by year, and whether "Liver Cirrhosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 1 | 1 | 2 |
1996 | 2 | 0 | 2 |
1997 | 1 | 4 | 5 |
1998 | 4 | 1 | 5 |
1999 | 0 | 3 | 3 |
2000 | 3 | 2 | 5 |
2001 | 2 | 1 | 3 |
2002 | 2 | 4 | 6 |
2003 | 3 | 3 | 6 |
2004 | 0 | 2 | 2 |
2005 | 3 | 1 | 4 |
2006 | 5 | 3 | 8 |
2007 | 3 | 2 | 5 |
2008 | 7 | 1 | 8 |
2009 | 6 | 4 | 10 |
2010 | 6 | 1 | 7 |
2011 | 6 | 2 | 8 |
2012 | 5 | 3 | 8 |
2013 | 5 | 2 | 7 |
2014 | 7 | 2 | 9 |
2015 | 10 | 4 | 14 |
2016 | 17 | 4 | 21 |
2017 | 12 | 5 | 17 |
2018 | 10 | 3 | 13 |
2019 | 12 | 2 | 14 |
2020 | 4 | 8 | 12 |
2021 | 3 | 15 | 18 |
2022 | 0 | 9 | 9 |
2023 | 0 | 14 | 14 |
2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Liver Cirrhosis" by people in Profiles.
-
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024 Feb 08; 390(6):497-509.
-
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024 Mar; 9(3):218-228.
-
Implementation of a liver health check in people with type 2 diabetes. Lancet Gastroenterol Hepatol. 2024 Jan; 9(1):83-91.
-
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis. Diabetes Obes Metab. 2024 Jan; 26(1):191-200.
-
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis. Hepatology. 2024 Mar 01; 79(3):674-689.
-
Hepatocellular carcinoma surveillance may be associated with potential psychological harms in patients with cirrhosis. Hepatology. 2024 Jan 01; 79(1):107-117.
-
Natural history of NASH cirrhosis in liver transplant waitlist registrants. J Hepatol. 2023 10; 79(4):1015-1024.
-
Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models. Int J Mol Sci. 2023 Jun 10; 24(12).
-
Reply: ELF in the risk stratification of NAFLD-Are the ELF thresholds suggested by the AASLD guidelines appropriate? Hepatology. 2023 Dec 01; 78(6):E103-E104.
-
Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database. BMC Gastroenterol. 2023 May 19; 23(1):160.